Catalyst Pharmaceutical Inc. - CPRX STOCK NEWS

Catalyst Pharmaceuticals (CPRX) is set to release its Q1 2023 financial results after market close on May 10, 2023. A conference call and webcast discussing the results will take place on May 11, 2023, at 8:30 AM ET. The company specializes in developing innovative medicines for rare diseases, with its key product being FIRDAPSE for Lambert-Eaton myasthenic syndrome. Additionally, Catalyst recently acquired U.S. commercial rights to FYCOMPA, an epilepsy treatment approved for patients aged four and older. The company highlights its commitment to patient care and innovative solutions in the biopharmaceutical sector. Investors can access the webcast via their official website, where a replay will be available for 30 days.

Catalyst Pharmaceuticals (Nasdaq: CPRX) announced the upcoming presentation of four abstracts related to FYCOMPA (perampanel) at the AAN 2023 Annual Meeting in Boston, MA, from April 22-27, 2023. These studies, presented by Eisai, detail the efficacy of FYCOMPA in treating various types of seizures in patients aged four and older, including those with psychiatric histories and Lennox-Gastaut Syndrome. Catalyst's Chief Medical Officer, Gary Ingenito, emphasized the importance of these findings in enhancing understanding of perampanel's therapeutic benefits. FYCOMPA is indicated for partial-onset seizures and primary generalized tonic-clonic seizures. It is available in multiple dosages and is prescribed globally to over 500,000 patients.

Catalyst Pharmaceuticals (CPRX) reported record total net revenues of $214 million for 2022, marking a 52% year-over-year increase. FIRDAPSE® alone contributed $61 million in Q4 2022, up 59% from the previous year. The recent acquisition of FYCOMPA® is projected to enhance EBITDA and EPS in 2023, with total net product revenue guidance between $375 million and $385 million. The company ended 2022 with $298 million in cash, poised for further product portfolio diversification and expansion. Catalyst has strengthened its patent portfolio and continues to drive strategic initiatives, demonstrating strong financial performance and growth potential.

Catalyst Pharmaceuticals announced positive findings regarding FYCOMPA® (perampanel) for treating rare genetic epileptic diseases. An article in Epilepsia reported that 43.5% of 137 patients experienced over a 75% reduction in seizure frequency, with 27.5% achieving over a 90% reduction. This high efficacy was noted among various genetic mutations such as SCN1A and GNAO1. Dr. Gary Ingenito emphasized the potential of FYCOMPA® in managing these challenging conditions. Additionally, Catalyst acquired the U.S. rights to FYCOMPA® in January 2023, expanding its portfolio, which includes FIRDAPSE® for Lambert-Eaton myasthenic syndrome.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) will release its fourth quarter and full-year 2022 financial results after market close on March 15, 2023. The management team will host a conference call and webcast on March 16, 2023, at 8:30 AM ET to discuss these results and provide a corporate update. Catalyst focuses on developing and commercializing innovative medicines for rare diseases, with its flagship product, FIRDAPSE®, approved for treating Lambert-Eaton myasthenic syndrome. In January 2023, it acquired rights to FYCOMPA®, enhancing its epilepsy treatment portfolio.

Catalyst Pharmaceuticals (CPRX) will ring the Nasdaq Closing Bell on February 28, 2023, in celebration of International Rare Disease Day. This event aims to raise awareness for the critical needs of individuals with rare diseases, with support from advocacy groups. CEO Patrick McEnany highlighted the importance of innovative treatments for rare conditions, while advocacy leaders stressed the necessity for increased awareness and timely diagnosis. Over 25 million Americans are affected by rare diseases, necessitating urgent action and support for better treatment options. Catalyst's commitment to these communities is underscored by its product pipeline, including FIRDAPSE and FYCOMPA.

Catalyst Pharmaceuticals (Nasdaq: CPRX) reported preliminary estimates indicating 2022 total revenues of approximately $214 million, a 52% year-over-year growth. The fourth quarter revenue is estimated at $61 million, a 61% increase compared to Q4 2021. For 2023, the company forecasts total revenues between $375 million and $385 million, representing a 75% to 80% growth. FIRDAPSE net revenues for 2023 are projected at $245 million to $255 million, while FYCOMPA is expected to generate $130 million for approximately 11 months of sales. Catalyst ended 2022 with around $298 million in cash and equivalents, positioning itself to capitalize on its expanded product portfolio.